Guy's and St Thomas' Hospital

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Bladder cancer2 trials
• Myeloproliferative neoplasms2 trials
• Atrial fibrillation1 trial
• Childhood cancers1 trial
• Lung cancer1 trial
• Mesothelioma1 trial
• Multiple myeloma1 trial
• Ovarian cancer1 trial
• Prostate cancer1 trial
• Type 1 diabetes1 trial
• Ulcerative colitis1 trial

Phase

• Phase 13 trials
• Phase 22 trials
• Phase 32 trials
• Phase 2/31 trial

Status

• Completed4 trials
• Active, not recruiting3 trials
• Recruiting1 trial
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Janssen Research & Development, LLC3 trials
• AtriCure, Inc.1 trial
• ETOP IBCSG Partners Foundation1 trial
• Imcyse SA1 trial
• Institute of Cancer Research, United Kingdom1 trial
• and 3 more

Running trials

• Recruiting

  A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

  NCT06150157· Phase 1· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

  NCT04136353· Phase 3· University of Sydney· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study of Tumour Focused Radiotherapy for Bladder Cancer

  NCT02447549· Phase 2· Institute of Cancer Research, United Kingdom· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myeloproliferative neoplasms1 recruiting

Closed trials

• Completed

  A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

  NCT05444530· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

  NCT05366725· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Withdrawn

  CONVERGE CAP Study-For The Treatment Of Symptomatic Persistent or Long-standing Persistent AF

  NCT04239534· AtriCure, Inc.· Source

• Terminated

  IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

  NCT04524949· Phase 2· Imcyse SA· Source

• Completed

  BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

  NCT03762018· Phase 3· ETOP IBCSG Partners Foundation· Source

• Completed

  Phase I Trial of VS-6766 Alone and in Combination With Everolimus

  NCT02407509· Phase 1· Royal Marsden NHS Foundation Trust· Source